Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
NEVANAC 1 mg/ml eye drops, suspension.
Pharmaceutical Form |
---|
Eye drops, suspension. Light yellow to light orange uniform suspension, pH 7.4 (approximately). |
1 ml of suspension contains 1 mg nepafenac.
Excipient with known effect: Each ml of suspension contains 0.05 mg of benzalkonium chloride.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Nepafenac |
Nepafenac is a non-steroidal anti-inflammatory and analgesic prodrug. After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a nonsteroidal anti-inflammatory drug. Amfenac inhibits the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production. |
List of Excipients |
---|
Mannitol (E421) |
5 ml round low density polyethylene bottle with a dispensing plug and white polypropylene screw cap containing 5 ml suspension.
Carton containing 1 bottle.
Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
EU/1/07/433/001
Date of first authorisation: 11 December 2007
Date of latest renewal: 24 September 2012
Drug | Countries | |
---|---|---|
NEVANAC | Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Nigeria, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.